Idioma:

Comparative Study of Basiliximab Treatment in Lung Transplantation

Borro, J.M. ; De la Torre, M. ; Mı́guelez, C. ; Fernandez, R. ; Gonzalez, D. ; Lemos, C.

Transplantation proceedings, 2005-11, Vol.37 (9), p.3996-3998 [Periódico revisado por pares]

New York, NY: Elsevier Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Comparative Study of Basiliximab Treatment in Lung Transplantation
Autor: Borro, J.M. ; De la Torre, M. ; Mı́guelez, C. ; Fernandez, R. ; Gonzalez, D. ; Lemos, C.
Assuntos: Adult ; Aged ; Antibodies, Monoclonal - therapeutic use ; Biological and medical sciences ; Female ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Graft Rejection - epidemiology ; Humans ; Immunosuppressive Agents - therapeutic use ; Lung Diseases - classification ; Lung Transplantation - immunology ; Lung Transplantation - mortality ; Male ; Medical sciences ; Methylprednisolone - therapeutic use ; Middle Aged ; Recombinant Fusion Proteins - therapeutic use ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Survival Analysis ; Time Factors ; Tissue, organ and graft immunology
É parte de: Transplantation proceedings, 2005-11, Vol.37 (9), p.3996-3998
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: This study compared the incidence of acute or chronic rejection and adverse events in lung transplant patients receiving induction basiliximab versus controls not receiving treatment. Basiliximab was administered to 15 patients with impaired renal function, advanced age, or high surgical risk, (group I). The mean age was 48.9 years; nine were double-lung and six single-lung grafts. They were compared to 13 lung transplants performed in 2001 (mean age 43.6 years, 11 double lung and two single lung [group II]). The incidence of acute rejection was 13.3% in group I versus 38.5% in group II ( P = .19, OR 4.06), with chronic rejection in 20% and 38.5% of cases, respectively ( P = .4, OR 2.5). No significant differences were observed in the incidence of infections or malignancies. Nor were there any direct adverse events due to the administration of the drug. The estimated 2-year survival was 80% for group I and 54% for group II ( P = .14). Basiliximab has a trend to reduce the rate of acute and chronic rejection in lung transplant recipients, with no increased incidence of infections or malignancies. The 2-year survival for patients treated with basiliximab was better than the control group, despite including high risk transplant patients.
Editor: New York, NY: Elsevier Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Comparative Study of Basiliximab Treatment in Lung Transplantation

Borro, J.M. ; De la Torre, M. ; Mı́guelez, C. ; Fernandez, R. ; Gonzalez, D. ; Lemos, C.

New York, NY: Elsevier Inc

Buscando em bases de dados remotas. Favor aguardar.